

RESEARCH

Open Access



The impact of irritable bowel syndrome on health-related quality of life in women with polycystic ovary syndrome

Fatemeh Bazarganipour¹, Seyed-Abdolvahab Taghavi², Zatollah Asemi³, Helen Allan⁴, Zahra Khashavi⁵, Tahereh Safarzadeh⁶, Shamsi Pourchangiz⁶, Fatemeh Zare⁶, Samaneh Ghasemi⁶, Zivar Karimi⁶ and Maryam Azizi Kutenae^{7*}

Abstract

Background: The objectives of this study were to compare the prevalence and quality of life (QOL) of irritable bowel syndrome (IBS) in women with polycystic ovary syndrome (PCOS) compared with healthy women.

Methods: This was a case-control study of 201 women recruited at an infertility clinic in Iran. The control group were healthy women ($n = 100$) and the comparison group, women with PCOS ($n = 101$). Data were collected by clinical Rome III criteria to determine the IBS, Bristol scale for stool consistency and IBS QOL.

Results: The reporting of IBS symptoms were higher in PCOS (20.7%) than control group (11%) ($P = 0.05$). The IBS QOL score in the IBS + PCOS group was lower than other groups (IBS+ non PCOS, non IBS + PCOS, non IBS+ non PCOS; scores in food avoidance and worries about health domains were significant ($P < 0.01$).

Conclusions: We conclude that having PCOS and an increased level of LH/FSH tends to cause IBS symptoms. IBS + PCOS women experience significant impaired quality of life scores particularly in relation to worries about health and food avoidance. These results offer further insights into IBS in PCOS women and their functional status and wellbeing.

Keywords: Polycystic ovary syndrome, Irritable bowel syndrome, Quality of life

Introduction

Irritable bowel syndrome (IBS) is one of the most common disorders of the digestive system, with a 10–20% incidence globally [1]. People with IBS have sensitive intestines and suffer from intestinal muscle spasms in response to food, gas, and stress. These spasms can lead to abdominal cramps and pains, changes in bowel function, bloating, diarrhoea, and constipation [2]. Patients with IBS also experience higher rates of absence from work, disruption of interpersonal relations, including a reluctance to

have sexual intercourse. IBS can prevent patients from attending social gatherings and travelling for fear of experiencing symptoms in public. Many studies have reported a lower level of the quality of life (QOL) for these patients than the general population [3–6].

Although studies have shown that the prevalence of IBS in women is twice that of men generally, it was believed that this disorder was lower in women with PCOS compared to healthy women. However a recent study reported an increased prevalence of IBS in women with PCOS compared to healthy women [7]. Polycystic ovarian syndrome (PCOS) is a common chronic endocrine disease which affects 5–10% of women of reproductive age. It is characterized by chronic anovulation, with

* Correspondence: maryamazikut86@gmail.com

⁷Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

clinical or laboratory signs of hyperandrogenism [8]. Obesity is prevalent in women with PCOS due to elevated androgen levels [9]. However, there is no detailed description of the relationship between IBS and women with PCOS symptoms in relation to raised androgen levels and raised body mass index (BMI) [7].

These factors influenced the decision to investigate the prevalence of IBS in women with PCOS compared to healthy women and to compare QOL in a group of women with PCOS and healthy women.

Methods

Design and data collection

This was a case-control study of women with PCOS who attended an infertility clinic at a hospital in Hormozgan Province, Iran from May to September 2014. This clinic is the only referral center for infertility in the province. The sample size (201) was calculated using Mathur, et al., (2010) information. Women with a confirmed diagnosis of PCOS ($n = 300$) were invited to participate in the study as a case comparison group. After explaining the study objectives and obtaining written consent from each woman, final participants were randomly allocated to the PCOS ($n = 101$); a control group of healthy women whose partners had a diagnosis of male infertility ($n = 100$) were approached in the same way. Inclusion criteria were include being 15–40 years of age [10–17]; married; absence of non-classic adrenal hyperplasia, thyroid dysfunction, hyperprolactinemia; non-smoking; absence of following warning signs that rejected IBS included extreme weight loss over the past few months, fever, nocturnal symptoms, severe chronic constipation, diarrhea, frequent vomiting, progressive dysphasia, a history of travel to areas of parasitic infections, family history of colon cancer, inflammatory bowel disease; not having cough (bronchitis) during the last 3 months; no problems in speaking or listening; Iranian; not taking any prescription medication (except allergy medications and occasional pain medications) for at least 3 months before entering the study; having two of the following Rotterdam diagnostic criteria:

- 1) Polycystic ovaries visualized on ultrasound scan (presence of 12 follicles or more in one or both ovaries and/or increased ovarian volume i.e., > 10 ml),
- 2) Clinical signs of hyperandrogenism (hirsutism score based on hirsutism score greater than 7 or obvious acne),
- 3) having an interval between menstrual periods > 35 days and/or amenorrhea, defined as the absence of vaginal bleeding for at least 6 months (i.e. 199 days).

The women were requested to complete the study measures in clinic.

Measures

1. Menstrual history: all women were asked for the interval between menstrual periods during the preceding 12 months; results were categorized to < 21 days, 21–34 days, 35–60 days (oligomenorrhea), > 199 days (amenorrhea) and variable.
2. BMI: weight and height were calculated by weight/height squared [kg/m^2] in all women.
3. Body hair: Clinical assessment of hirsutism in all women was determined using the Ferriman-Gallwey Scoring System (F/G score). Nine body sites (the upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, arm, and thigh) were graded from 0 (no terminal hair) to 4 (severe hirsutism). Scores can range from zero to 36. A score of seven or above was considered positive for hirsutism [18].
4. Acne: the Global Acne Grading System (GAGS) was used to determine acne in all women. The GAGS assesses six locations on the face and chest/upper back, calculating surface area, distribution, and density of pilosebaceous units of lesions. Each of the six locations is graded separately on a scale 0-to-4, with the most severe lesion within that location determining the local score. The global score is a summation of all local scores [19].
5. Socio-demographic status: The study used years of formal education as a measure of socioeconomic status, categorized into five levels: no education, first level (1 to 5 years), second level (6–9 years), third level (10–12 years) and fourth level (more than 12 years). Donyavi et al., (2011) show that education is a good proxy measure for socioeconomic status for Iranians.
6. Laboratory measures: An overnight or 8 h fasting venous blood sample was obtained from each patient. Follicle-stimulating hormone (FSH) and Luteinizing hormone (LH) were assessed in all participants by ELIZA (DRG Instruments GmbH, Marburg, Germany).
7. ROME III diagnostic criteria: since IBS has no structural disorder or biochemical signs, the diagnosis is based on clinical signs. The ROME III criteria for the diagnosis of IBS (2006) includes intermittent abdominal pain on at least 3 days of the month in the last 3 months with at least two of the following three criteria combined: (i) abdominal pain or discomfort improves with defecation, (ii) abdominal pain or discomfort starts with a change in frequency of defecation, (iii) abdominal pain or discomfort start with a change in stool consistency (appearance). It should be noted that the above criteria must be present in the last 3 months before

the diagnosis, as well as at least last 6 months from the onset of symptoms. The validity and reliability of these tools are approved in Iran [20].

8. IBS-QOL questionnaire was designed by Patrick, et al., (1998) and contains 34 items with a five degree Likert scale. There are eight domains: dysphoria, relationships, sexual concern, health worry, social reaction, body image, food avoidance, and interference with activity. Scores were between 0 to 100; a higher score in this tool represents a worse quality of life [21]. The validity and reliability of these tools are approved in Iran.
9. Bristol scale stool consistency: Bristol stool form scale is a medical aid designed to classify the form of human feces into seven categories including type 1: Separate hard lumps, like nuts (hard to pass); type 2: sausage-shaped, but lumpy; type 3: like a sausage but with cracks on its surface; type 4: like a sausage or snake, smooth and soft; type 5: soft blobs with clear cut edges (passed easily); type 6: fluffy pieces with ragged edges, a mushy stool; type 7: watery, no solid pieces, entirely liquid. Types one and two indicate constipation, with three and four being the ideal stools (especially the latter), as they are easy to defecate while not containing excess liquid, and five, six and seven tending towards diarrhea [22].

Statistical analysis

Data were presented as mean ± Standard Deviation (SD) and frequency (percent) for quantitative and qualitative variables, respectively. Pearson Chi square test was used to compare demographic variables in the two groups. Ordinal demographic variables were compared between the two groups using the Mann-Whitney U test. Independent samples t-test was used to compare the means of in two groups.

Ethical considerations

The Ethics Committee of the Hormozgan Medical University reviewed the study.

Results

The study sample

Over a period of 6 months, 201 women were recruited to the study. The socioeconomic and clinical characteristics of patients are presented in Table 1. There was a significant difference between the two groups in terms of PCOS related features (such as acne, hirsutism and menstrual pattern and LH/FSH ratio) ($P < 0.001$).

IBS subtype & stool frequency

IBS cases in women with PCOS was 29.7% and the control group 11% ($P < 0.01$). The highest number of PCOS

Table 1 Socio-demographic & clinical characteristics in patients

	PCOS (n = 101)	Control (n = 100)	P value
Age (year)	28 ± 4.92	29.68 ± 5.36	0.02
Education (year)	11.74 ± 3.53	10.77 ± 3.84	0.06
BMI	25.52 ± 4.70	24.53 ± 3.88	0.1
Occupation			
Occupied	18	19	0.82
Housewife	83	81	
Parity	0.16 ± 0.42	0.15 ± 0.35	0.74
Menstruation			
< 21	2 (1.98)	2 (2)	< 0.001
21–35	34 (33.66)	79 (79)	
35–60	17 (16.83)	6 (6)	
> 3 month	7 (6.93)	1 (1)	
Variable	41 (40.59)	12 (12)	
Hirsutism score	3.35 ± 3.15	0.58 ± 1.39	< 0.001
Acne score	4.20 ± 5.01	1.76 ± 3.8	< 0.001
LH/FSH	1.88 ± 1.52	0.93 ± 1.21	< 0.001

women placed in subtype of IBS – Constipation (20.8). According to Bristol stool consistency scale, women were in 2rd and 3rd rank (sausage-shaped, but lumpy; and like a sausage but with cracks on its surface, respectively) that matches with IBS-Constipation relatively (Table 2).

Comparison of sum scores of IBSQOL

There was significant difference in QOL scores between two groups ($P < 0.001$) mainly in food avoidance and worries about health (Table 3). In other word, in PCOS

Table 2 IBS subtype and bristol scale stool consistency in patients

	PCOS (n = 101)	Control (n = 100)	P value
IBS subtype			
No IBS	71 (70.3)	89 (89)	0.002
IBS-C	21 (20.8)	5 (5)	
IBS-D	4 (4)	2 (2)	
IBS-M	5 (5)	4 (4)	
Bristol scale stool consistency			
0	71 (70.3)	89 (89)	< 0.001
1	4 (4)	2 (2)	
2	7 (6.9)	3 (3)	
3	10 (9.9)	3 (3)	
4	5 (5)	1 (1)	
5	2 (2)	1 (1)	
6	2 (2)	1 (1)	
7	–	–	

Table 3 comparison the IBS-QOL scores in patients

	PCOS (n = 101)		Control (n = 100)		P value ^b
	IBS	No IBS	IBS	No IBS	
Overall	60.71 ± 13.30	99.46 ± 2.98	74.13 ± 20.92	98.40 ± 6.02	< 0.001
P value ^a	< 0.001		< 0.001		
Dysphoria	61.30 ± 13.94	99.64 ± 2.96	75.94 ± 2.77	99.39 ± 6.04	< 0.001
P value	< 0.001		< 0.001		
Interference with activity	60.83 ± 12.96	99.64 ± 2.96	74.02 ± 20.70	98.35 ± 6.16	< 0.001
P value	< 0.001		< 0.001		
Relationship	61.38 ± 12.58	99.64 ± 2.96	75 ± 23.27	98.04 ± 6	< 0.001
P value	< 0.001		< 0.001		
Sexual	61.66 ± 14.28	99.64 ± 2.96	76.13 ± 12.97	98.31 ± 6.30	< 0.001
P value	< 0.001		< 0.001		
Health worry	60.05 ± 13.79	99.64 ± 2.98	73.48 ± 21.02	98.59 ± 5.78	< 0.001
P value	< 0.001		< 0.001		
Food avoidance	59.72 ± 13.80	99.64 ± 2.96	70.45 ± 21.20	98.31 ± 6.30	< 0.001
P value	< 0.001		< 0.001		
Social reaction	61.85 ± 13.36	99.64 ± 2.96	75 ± 21.83	98.52 ± 5.80	< 0.001
P value	< 0.001		< 0.001		
Body image	61.66 ± 13.90	99.64 ± 2.96	73.29 ± 20.17	98.31 ± 6.30	< 0.001
P value	< 0.001		< 0.001		

^aBetween IBS and no IBS in PCOS / control groups, separately

^bBetween PCOS and control groups with IBS

patients the lowest scores of QOL were belong to IBS subgroup. Similarly, in control group the lowest scores of QOL were belong to IBS subgroup. Moreover, the IBS+ PCOS patients had lower QOL scores than IBS+ non PCOS patients.

Discussion

In this study, IBS cases in patients with PCOS (29.7%) by using Rome III criteria is higher than the values reported in the general population. Mathur et al. (2010) have also reported the IBS prevalence 41.7% by criteria Rome I in women with PCOS. Several studies in Iran have also reported the prevalence of IBS in different populations. The prevalence of IBS in Iranian blood donors was 5.6% [23]. The prevalence of IBS in 18,180 people in five cities in Tehran province was estimated to be about 1% by employing Rome III criteria [24]. Several issues may contribute to such the wide range reported in these studies which use different diagnostic criteria for IBS. Rome III is less restrictive than Rome II which demands patients to report their symptoms over longer periods. Compared to Rome III, a higher number of patients self diagnose with IBS using Rome II. Therefore, it's seemed that the prevalence estimated by Rome III is lower than Rome II and I [25]. proposes using Rome III criteria in studies. Moreover, the role of socioeconomic

status and cultural differences should be taken into account. Ho et al., 1998 suggested that the IBS in the urban group more than rural probably because the urban group reported a significantly greater influence of stress than the rural group. It is believed that the prevalence of IBS is less in developing countries (like Iran) compared to western countries [26, 27].

Increased levels of ovarian hormones decrease gastrointestinal transit [28]. Therefore women with IBS report the symptoms related to constipation more than men, except at the time of menstruation when hormone levels have reduced [29]. In the present study, the majority of patients with PCOS (20.8%) have IBS dominant constipation (IBS-C). It seems the cause of this variant of IBS is due to the high levels of hormones in PCOS which interference with bowel function. However, if only the hyper-androgenic condition is involved in the increased risk of IBS, it might be expected that IBS cases in the PCOS group should be less than the control groups.

Stress can affect the gastrointestinal function, so that the start and the severity of the symptoms of IBS are related to acute and chronic stress. Therefore, patients with IBS have hyperactivity to stress (excessive response of limbic system to the stress) [30]. A history of adverse life events and stress cause changes in the hypothalamic–pituitary–adrenal axis response to stress and

inappropriate signaling of Corticotropin-releasing hormone as the most important factor in the increased prevalence of IBS [31]. Previous studies have reported that women with PCOS have more anxiety and stress which may cause a higher prevalence of IBS in these patients [32]. In addition to PCOS, an increase in the amount of LH/FSH was also an important predictor variable of IBS. In women with PCOS, the LH/FSH ratio was higher and it seems that an increase the perceived stress by patients may lead to increased sensitivity of the hypothalamic–pituitary–adrenal axis and LH and consequently a higher prevalence of IBS in these patients. Use of gonadotropin releasing hormone analogue leuprolide acetate which dramatically decreases LH which would be improves of chronic abdominal pain in women [33].

IBS has a strong effect on the quality of life in women are diagnosed with it as it imposes substantial social and economic costs due to the need for medical care and absenteeism at work. One study in Iran investigated the economic burden of IBS and showed the cost of IBS in Iran about 2.8 million dollars and this is of great significant for Iranian population [34].

There are no specific biomarkers to assess the condition of patients with IBS. Thus there needs to be increased attention to the non-pathological markers in evaluating the impact of IBS as a chronic disease on well being, daily functioning and QOL. According Frank et al., (2002) patients with IBS have poor QOL compared to the general population; the same authors emphasize that IBS has a greater negative impact on QOL than asthma, gastroesophageal reflux disease (GERD) or migraine headaches. In the present study, QOL in women with IBS in both groups was significantly lower than in women without IBS. In both groups, worries about health and food avoidance were the areas of QOL most affected by IBS. Sung Kim et al. (2010) reported that the most affected areas were dysphonia, worries about health and the food avoidance [35]. These findings suggests that in our patients like Korean female with IBS, IBS patients suffer more from anxiety about their disease than impairment of social activity or relationship by bowel symptom.

Studies on women with PCOS using an IBS specific QOL tools have not been found identified in the literature; our study is the first to use IBS specific QOL measures in women with PCOS compared to healthy women. Studies using SF36 [36] and WHOQOL [37] to measure QOL minimize the influence of gastrointestinal symptoms on general QOL. Specific QOL tools associated with IBS have been designed and validated and include specific areas associated with QOL most affected by IBS.

Limitations

There are some limitations in our study. The study population is from a limited region of Iran and is not be

representative of the general population either in Iran or other countries. Moreover, there are unmeasured covariates that may play an important role in the association between IBS and PCOS, for example, psychological history; that IBS was self-identified may be another limitation.

Conclusion

As the results of this study show, having PCOS and an increased level of LH/FSH might cause IBS. IBS + PCOS patients experience significant effects on QOL particularly in relation to worries about health and food avoidance. These data offer insights for clinicians into IBS in women with PCOS and their functional status and wellbeing.

Abbreviations

QOL: Quality of life; IBS : Irritable bowel syndrome; PCOS: Polycystic ovary syndrome; BMI: Body mass index; GAGS: Global Acne Grading System; FSH: Follicle-stimulating hormone; LH: Luteinizing hormone

Acknowledgements

Not Applicable.

Authors' contributions

FB and MA contributed in conception, design and drafting of the manuscript. FB,SAT,ZA,HA,SKH,TS,SHP,FZ,SGH,Zk and MA contributed in data collection. FB,SAT and MA contributed in manuscript drafting. All authors approved the final version for submission. FB oversaw the study.

Funding

The research grant provided by Research Deputy of Hormozgan University of Medical Sciences (HUMS). The role of the funding body was collection and analysis.

Availability of data and materials

The primary data for this study is available from the authors (Fateme Bazarganipour) on direct request.

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments. Study protocol was approved by the research ethics committee of Hormozgan University of Medical Sciences (HUMS). Written informed consent of all children was obtained. In addition, parental consent was obtained for all participants and the consent was also provided in written form.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Author details

¹Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran. ²Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran. ³Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, IR, Iran. ⁴Centre for Critical Research in Nursing & Midwifery, School of Health & Education, Middlesex University, London, UK. ⁵Infertility Clinic, Omeleila Hospital, Bandar Abbas, Hormozgan, Iran. ⁶Student Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. ⁷Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Received: 13 June 2019 Accepted: 2 June 2020

Published online: 13 July 2020

References

- Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. *BMJ (Clinical research ed)*. 2006;332(7536):280–3 Epub 2006/02/04.
- Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, et al. An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol*. 2009;104(Suppl 1):S1–35 Epub 2009/06/19.
- Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. *Pharmacoeconomics*. 2001;19(6):643–53 Epub 2001/07/18.
- Brun-Strang C, Dapigny M, Lafuma A, Wainstein JP, Fagnani F. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. *Eur J Gastroenterol Hepatol*. 2007;19(12):1097–103 Epub 2007/11/14.
- Wilson A, Longstreth GF, Knight K, Wong J, Wade S, Chiou CF, et al. Quality of life in managed care patients with irritable bowel syndrome. *Manag Care Interface*. 2004;17(2):24–8 34. Epub 2004/03/25.
- Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. *Clin Ther*. 2002;24(4):675–89 discussion 4. Epub 2002/05/23.
- Mathur R, Ko A, Hwang LJ, Low K, Azziz R, Pimentel M. Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. *Dig Dis Sci*. 2010;55(4):1085–9.
- Mason H, Colao A, Blume-Peytavi U, Rice S, Qureshi A, Pellatt L, et al. Polycystic ovary syndrome (PCOS) trilogy: a translational and clinical review. *Clin Endocrinol*. 2008;69(6):831–44 Epub 2008/07/12.
- Douchi T, Yamamoto S, Oki T, Maruta K, Kuwahata R, Nagata Y. Serum androgen levels and muscle mass in women with polycystic ovary syndrome. *Obstet Gynecol*. 1999;94(3):337–40 Epub 1999/09/03.
- Bazarganipour F, Ziaei S, Montazeri A, Foroozanfar F, Kazemnejad A, Faghihzadeh S. Sexual functioning among married Iranian women with polycystic ovary syndrome. *Int J Fertil Steril*. 2014;8(3):273–80 Epub 2014 Nov 1.
- Bazarganipour F, Ziaei S, Montazeri A, Foroozanfar F, Faghihzadeh S. Iranian version of modified polycystic ovary syndrome health-related quality of life questionnaire: discriminant and convergent validity. *Iran J Reprod Med*. 2013;11(9):753–60.
- Bazarganipour F, Ziaei S, Montazeri A, Foroozanfar F, Faghihzadeh S. Health-related quality of life and its relationship with clinical symptoms among Iranian patients with polycystic ovarian syndrome. *Iran J Reprod Med*. 2013;11(5):371–8.
- Bazarganipour F, Ziaei S, Montazeri A, Foroozanfar F, Kazemnejad A, Faghihzadeh S. Body image satisfaction and self-esteem status among the patients with polycystic ovary syndrome. *Iran J Reprod Med*. 2013;11(10):829–36.
- Bazarganipour F, Ziaei S, Montazeri A, Foroozanfar F, Kazemnejad A, Faghihzadeh S. Health-related quality of life in patients with polycystic ovary syndrome (PCOS): a model-based study of predictive factors. *J Sex Med*. 2014;11(4):1023–32. <https://doi.org/10.1111/jsm.12405> Epub 2013 Dec 6.
- Bazarganipour F, Ziaei S, Montazeri A, Foroozanfar F, Kazemnejad A, Faghihzadeh S. Psychological investigation in patients with polycystic ovary syndrome. *Health Qual Life Outcomes*. 2013;11:141. <https://doi.org/10.1186/477-7525-11-141>.
- Bazarganipour F, Ziaei S, Montazeri A, Foroozanfar F, Kazemnejad A, Faghihzadeh S. Predictive factors of health-related quality of life in patients with polycystic ovary syndrome: a structural equation modeling approach. *Fertil Steril*. 2013;100(5):1389–96. <https://doi.org/10.1016/j.fertnstert.2013.06.043> Epub Jul 25.
- Bazarganipour F, Ziaei S, Montazeri A, Faghihzadeh S, Frozanfar F. Psychometric properties of the Iranian version of modified polycystic ovary syndrome health-related quality-of-life questionnaire. *Hum Reprod*. 2012; 27(9):2729–36. <https://doi.org/10.1093/humrep/des199> Epub 2012 Jun 26.
- Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. *J Clin Endocrinol Metab*. 1961;21:1440–7 Epub 1961/11/01.
- Lever WF, Schaumburg-Lever G. *Acne vulgaris*. *Histopathology of the Skin*. 7th edn Philadelphia. JB Lippincott. 1990;218:9.
- Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. *J Gastrointestinal Liver Dis*. 2006;15(3):237–41 Epub 2006/10/03.
- Patrick DL, Drossman DA. Re: Groll et al.—Comparison of IBS-36 and IBS-QOL instruments. *Am J Gastroenterol*. 2002;97(12):3204 author reply –5. Epub 2002/12/21.
- Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. *Scand J Gastroenterol*. 1997;32(9):920–4 Epub 1997/09/23.
- Hatami K, Pourshams A, Azimi K, Sarrafi M, Mehrabani M, Mostajabi P, et al. Dyspepsia, gastroesophageal reflux disease and irritable bowel syndrome among blood donors. *Govaresh*. 2003;8(4):138–46.
- Sorouri M, Pourhoseingholi MA, Vahedi M, Safaee A, Moghimi-Dehkordi B, Pourhoseingholi A, et al. Functional bowel disorders in Iranian population using Rome III criteria. *Saudi J Gastroenterol*. 2010;16(3):154–60 Epub 2010/07/10.
- Shen L, Kong H, Hou X. Prevalence of irritable bowel syndrome and its relationship with psychological stress status in Chinese university students. *J Gastroenterol Hepatol*. 2009;24(12):1885–90 Epub 2009/09/29.
- Danivat D, Tankeyoon M, Sriratanaban A. Prevalence of irritable bowel syndrome in a non-Western population. *British Medical J (Clinical research ed)*. 1988;296(6638):1710 Epub 1988/06/18.
- Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. *Am J Gastroenterol*. 1998;93(10):1816–22 Epub 1998/10/15.
- Heitkemper M, Jarrett M, Bond EF, Chang L. Impact of sex and gender on irritable bowel syndrome. *Biological Res Nurs*. 2003;5(1):56–65 Epub 2003/07/31.
- Lee OY, Mayer EA, Schmulson M, Chang L, Naliboff B. Gender-related differences in IBS symptoms. *Am J Gastroenterol*. 2001;96(7):2184–93.
- Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. *Gastroenterology*. 2002;123(5):1686–701.
- Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. *Gut*. 1992; 33(6):825–30 Epub 1992/06/01.
- Himelein MJ, Thatcher SS. Polycystic ovary syndrome and mental health: a review. *Obstet Gynecol Surv*. 2006;61(11):723–32 Epub 2006/10/19.
- Palomba S, Orio F Jr, Manguso F, Russo T, Falbo A, Lombardi G, et al. Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. *Fertil Steril*. 2005;83(4):1012–20 Epub 2005/04/12.
- Roshandel D, Rezaieashkajani M, Shafaei S, Zali MR. A cost analysis of functional bowel disorders in Iran. *Int J Color Dis*. 2007;22(7):791–9 Epub 2006/10/26.
- Kim YS, Choi SC, Park JM, Choi CH, Lee DH, Son HJ, et al. The effect of tegaserod on symptoms and quality of life in Korean women with irritable bowel syndrome with constipation. *J Neurogastroenterol Motil*. 2010;16(1): 61–70 Epub 2010/06/11.
- Icks A, Haastert B, Enck P, Rathmann W, Giani G. Health-related quality of life in subjects with functional bowel disorders in Germany. *Zeitschrift für Gastroenterologie*. 2002;40(10):863–7 Epub 2002/11/19.
- Jamali R, Biglari M. The comparison of WHOQOL-BREF with disease specific health related quality of life questionnaire in irritable bowel syndrome. *Acta medica Iranica*. 2015;53(11):717–24 Epub 2016/01/21.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.